论文部分内容阅读
来自于西班牙马德里La Paz医院的Jose R.Arribas博士及其同事在近期的《获得性免疫缺陷综合征》(AIDS)杂志上报道说,洛匹那韦/利托那韦与含2型核苷酸逆转录酶抑制剂(2NRTIs)药物联用可有效维持无法检测到HIV荷载。本项研究的负责人Arribas博士指出,研究结果表明实际上有一部分患者在无高危耐药环境暴露的情形下,采用洛匹那韦/利托那韦单一药物治疗即可维持病毒抑制状态。尽管针对HIV的三联药物疗法是成功的,但仍存在一些并发症。短期研究已证实洛匹那韦/利托那韦是有效的,且有可能适合做为单一药物以维持治疗。为深入探讨其机制,研究人员开展了一项包括42例患者的先导研究。
Jose R. Arribas, PhD, from La Paz Hospital in Madrid, Spain, and colleagues recently reported in the journal AIDS, that lopinavir / ritonavir was associated with a type 2 nucleoside Acid reverse transcriptase inhibitor (2NRTIs) drug combination can effectively maintain undetectable HIV load. Arribas, head of the study, points out that the results of the study show that in fact some patients are virus-suppressed with a single drug treatment of lopinavir / ritonavir in the absence of exposure to a high-risk drug-resistant environment. Although triple drug therapy for HIV is successful, there are still some complications. Short-term studies have confirmed that lopinavir / ritonavir is effective and may be suitable as a single agent to sustain treatment. To explore its mechanism in depth, researchers conducted a pilot study involving 42 patients.